Long term persistence of SARS-CoV-2 humoral response in multiple sclerosis subjects
暂无分享,去创建一个
V. De Rosa | M. D. Di Battista | A. Liotti | V. Manzo | G. Amato | G. Maniscalco | A. Viola | V. Andreone | A. L. Ferrara | Walter Di Iorio | Simona Salvatore | D. Graziano | G. Alfieri | O. Moreggia | Daniele Di Giulio Cesare | Gennaro Della Rocca
[1] S. Gharbia,et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.
[2] G. Tedeschi,et al. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod , 2022, Multiple Sclerosis and Related Disorders.
[3] V. De Rosa,et al. Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects , 2021, Multiple Sclerosis and Related Disorders.
[4] C. Agrati,et al. Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies , 2021, Neurology.
[5] A. Achiron,et al. Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study , 2021, Journal of Neuroimmunology.
[6] A. Achiron,et al. Humoral SARS-COV-2 IgG decay within 6 months in COVID-19 healthy vaccinees: The need for a booster vaccine dose? , 2021, European Journal of Internal Medicine.
[7] M. Ulivelli,et al. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies , 2021, EBioMedicine.
[8] A. Borobia,et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial , 2021, The Lancet.
[9] M. Davenport,et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[10] D. Centonze,et al. Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus , 2021, Journal of Neurology.
[11] E. Walsh,et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates , 2020, The New England journal of medicine.
[12] M. Dimopoulos,et al. Organ-specific manifestations of COVID-19 infection , 2020, Clinical and Experimental Medicine.
[13] M. Trojano,et al. Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide , 2020, Journal of the Neurological Sciences.
[14] D. Lauffenburger,et al. Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production , 2020, Cell.
[15] V. Meca-Lallana,et al. Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role? , 2020, Multiple Sclerosis and Related Disorders.
[16] M. Filippi,et al. COVID-19 in teriflunomide-treated patients with multiple sclerosis , 2020, Journal of Neurology.